Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Infosys Limited (INFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Infosys Limited — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.29 (market cap $8.04B), while Infosys Limited trades at $11.09 (market cap $46.90B). The key difference: Infosys Limited is far larger — about 5.8× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Infosys Limited pays a 4.74% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | INFY | |
|---|---|---|
Market Cap | $8.04B | $46.90B |
Sector | Health | Technology |
52-Week High | $339.75 | $20.22 |
52-Week Low | $241.71 | $10.49 |
Enterprise Value | $7.85B | $44.12B |
Dividend Yield | — | 4.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
INFY trades at $11.50, up 5.12% today, with a bullish technical signal and strong profitability metrics including a 16.44% net income margin and 31.57% ROE. Recent earnings beat expectations in Q4 2025 and Q1 2026, while the company is actively expanding AI collaborations in healthcare and financial services, as reported by PRNewsWire on June 24, 2026.
The stock offers a moderate valuation with a P/E of 13.81 and consensus price target of $12.14, suggesting modest upside. Risks include competitive pressures from AI automation and volatile IT spending, but institutional sentiment is mixed with 37.5% buy ratings. The dividend yield adds income appeal for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →
